How do you know if a particular medicine is working?
Traditionally, it takes guesswork on the physician’s part and time to find a drug that works for any given patient.
But what if we could leverage digital biomarkers to measure the efficacy of a medication very quickly and course correct as needed?
Rich Carter serves as Chief Digital Officer at Eli Lilly, where he oversees the teams focused on innovation, user-centered design and digital health.
On this episode of The Beat, Rich joins hosts Dr. Jessica Shepherd and Dr. Gautam Gulati to discuss the future of drug development and clinical trials.
Rich describes what digital transformation means in the context of life sciences, explaining how technology can improve drug discovery and accelerate the timeline from discovery to market.
Listen in for examples of the 35 digital biomarkers in development at Lilly and learn how Rich’s team thinks about partnering with both physicians and patients to roll out these new digital resources.
Topics Covered
Connect with Rich Carter
Connect with Dr. Gautam Gulati & Dr. Jessica Shepherd
Resources